Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lot B of Influenza virus vaccine · 1 trial · 1 indication
The immunologic equivalence of three consecutive production lots of the influenza virus vaccine was measured in terms of GMTs for all vaccine influenza strains.
| Arm | Type | Description |
|---|---|---|
| Influenza virus vaccine (lot A) | EXPERIMENTAL | Lot A of the investigational influenza virus vaccine |
| Influenza virus vaccine (lot B) | EXPERIMENTAL | Lot B of the investigational influenza virus vaccine |
| Influenza virus vaccine (lot C) | EXPERIMENTAL | Lot C of the investigational influenza virus vaccine |
| Influenza virus vaccine (pooled) | EXPERIMENTAL | Pooled data of all three lots (Lot A, B and C) of the investigational influenza virus vaccine |
| Comparator influenza vaccine | ACTIVE_COMPARATOR | A US licensed influenza virus vaccine |
| Name | Type | Description |
|---|---|---|
| Lot A of Influenza virus vaccine | BIOLOGICAL | 1 injection of the trivalent subunit influenza virus vaccine (lot A) administered intramuscularly |
| Lot B of Influenza virus vaccine | BIOLOGICAL | 1 injection of the trivalent subunit influenza virus vaccine (lot B) administered intramuscularly |
| Lot C of Influenza virus vaccine | BIOLOGICAL | 1 injection of the trivalent subunit influenza virus vaccine (lot C) administered intramuscularly |
| Comparator influenza virus vaccine | BIOLOGICAL | 1 injection of the trivalent subunit influenza virus vaccine administered intramuscularly |
| All 3 consecutive lots of influenza virus vaccine pooled | BIOLOGICAL | 1 injection of the pooled trivalent subunit influenza virus vaccine administered intramuscularly |
Inclusion Criteria: * 18 to 49 years of age; * In good health as determined by medical history and physical examination; * Able and willing to provide written informed consent prior to any study procedure; * Able to comply with all study procedures and available for all clinic visits scheduled in t...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE1 | Cell-based Trivalent Split Influenza Virus Vaccine, Egg-based Trivalent Split Influenza Virus Vaccine |
Lot B of Influenza virus vaccine is an investigational vaccine developed by Novartis AG for the prevention of influenza. It is a Phase 3 product that has been studied in a single completed clinical trial. The vaccine is designed to protect against influenza virus infection.
Lot B of Influenza virus vaccine is intended for the prevention of influenza in healthy adults. The clinical trial enrolled subjects 18 to 49 years old. The vaccine is being developed as a prophylactic measure against influenza virus infection.
Lot B of Influenza virus vaccine is developed by Novartis AG, which trades under the ticker symbol NVS. Novartis is the sponsor of the clinical program for this influenza vaccine candidate.
Lot B of Influenza virus vaccine is in Phase 3 clinical development. The single trial for this vaccine has been completed. It is an investigational product and has not been approved by the FDA.
Lot B of Influenza virus vaccine has been evaluated in one completed Phase 3 trial, NCT00617851, titled "Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old." The trial enrolled 1,507 participants in the Dominican Republic and was active-controlled, randomized, and double-blind.